1 – 10 of 33
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers : an international cohort study
Schrijver, Lieske H ; Antoniou, Antonis C ; Olsson, Håkan LU
; Mooij, Thea M
; Roos-Blom, Marie-José
; Azarang, Leyla
; Adlard, Julian
; Ahmed, Munaza
; Barrowdale, Daniel
and Davidson, Rosemarie
, et al.
(2021)
In American Journal of Obstetrics and Gynecology
Mark
- 2020
- Alcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers : Results from the BRCA1 and BRCA2 cohort consortium
- 2018
- The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant : Breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium
-
Oral Contraceptive Use and Breast Cancer Risk : Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study
Schrijver, Lieske H ; Olsson, Håkan LU
; Phillips, Kelly-Anne
; Terry, Mary Beth
; Goldgar, David E
; Kast, Karin
; Engel, Christoph
; Mooij, Thea M
; Adlard, Julian
and Barrowdale, Daniel
, et al.
(2018)
In JNCI Cancer Spectrum
2(2).
Mark
- Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations
- 2017
- Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression : identification of a modifier of breast cancer risk at locus 11q22.3
- 2016
- No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
- Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
- 2015
- Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers.
- An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.